Idiopathic Pulmonary Fibrosis
📧 Sign up to get email alerts when something new happens for Idiopathic Pulmonary Fibrosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-05Clinical Trial Results: Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis [Phase 1, Phase 2]
Phase 1/2 study of ARO-MMP7 inhalation solution in healthy participants and idiopathic pulmonary fibrosis patients has completed with result…
-
CLINICAL_TRIALS trial_result · 2026-08-05Clinical Trial Results: Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis [Phase 2]
Phase 2 randomized, double-blind trial of Bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis has terminated with posted results.
-
EMA approval · 2026-07-30EMA Authorised: Jascayd (nerandomilast) — Boehringer Ingelheim International GmbH
EMA authorised Jascayd (nerandomilast) for idiopathic pulmonary fibrosis, awarded to Boehringer Ingelheim International GmbH.
-
EMA approval · 2026-07-21EMA Authorised: Jascayd (nerandomilast) — Boehringer Ingelheim International GmbH
Jascayd (nerandomilast) has been authorised in the EU for idiopathic pulmonary fibrosis by Boehringer Ingelheim.
-
EMA approval · 2026-07-10EMA Authorised: Esbriet (Pirfenidone) — H.A.C. Pharma
Authorised status for Esbriet (pirfenidone) in the EU for idiopathic pulmonary fibrosis and related respiratory conditions.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-06-26Clinical Trial Results: Cough Reduction in IPF With Nalbuphine ER [Phase 2]
Phase 2 trial results evaluating nalbuphine ER for cough reduction in idiopathic pulmonary fibrosis have been completed with results posted.
-
EMA approval · 2026-06-25EMA Authorised: Nintedanib Accord (nintedanib) — Accord Healthcare S.L.U.
EU authorization of Nintedanib Accord for idiopathic pulmonary fibrosis and related interstitial lung diseases, expanding treatment options …
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis [Phase 2]
Phase 2 study update for CAL101 in idiopathic pulmonary fibrosis (IPF) is listed as active but not recruiting.
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. [Phase 2]
A Phase 2 clinical trial is evaluating Buloxibutid for efficacy and safety in idiopathic pulmonary fibrosis. The study is sponsored by Vicor…
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis [Phase 2]
A Phase 2 clinical trial to evaluate LTI-03 for idiopathic pulmonary fibrosis is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF [Phase 3]
Phase 3 confirmatory trial of HEC585 tablets for idiopathic pulmonary fibrosis is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-21Clinical Trial Update: Phase ll Study of HEC585 in Patients With IPF [Phase 2]
Phase 2 clinical trial update for HEC585 in idiopathic pulmonary fibrosis; the study is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis [Phase 1]
A Phase 1 trial evaluating safety, tolerability, and pharmacokinetics of MNKD-201 in idiopathic pulmonary fibrosis is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood [Phase 2]
A Phase 2 clinical trial in idiopathic pulmonary fibrosis is evaluating whether pirfenidone influences the blood concentration of BI-1015550…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast [Phase 3]
A Phase 3 follow-up trial is planned to assess long-term treatment with Nerandomilast in people with idiopathic pulmonary fibrosis or progre…
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: Real-life-persistence to Antifibrotic Treatments
A completed real-world study from Boehringer Ingelheim examining how patients with idiopathic pulmonary fibrosis persist with antifibrotic t…
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients [Phase 1]
A Phase 1 study evaluating oral Epigallocatechin-3-gallate (EGCG) in patients with Idiopathic Pulmonary Fibrosis has been completed.
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG Effect [Phase 1]
Phase 1 trial using collagen-targeted PET imaging to assess the effect of epigallocatechin gallate (EGCG) in idiopathic pulmonary fibrosis; …
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment [Phase 2]
This update describes a Phase 2 clinical trial evaluating BI 765423 for its effect on lung function in idiopathic pulmonary fibrosis, with o…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis [Phase 3]
A Phase 3 clinical trial is evaluating metformin to slow respiratory decline in idiopathic pulmonary fibrosis. The study is currently not re…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of RC010 Inhalation Powder in Healthy Participants [Phase 1]
Phase 1 study to evaluate safety, tolerability and pharmacokinetics of RC010 inhalation powder in healthy participants, with idiopathic pulm…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Evaluating the Efficacy and Safety of of HSK44459 in People With Idiopathic Pulmonary Fibrosis [Phase 2]
A Phase 2 clinical trial evaluating the efficacy and safety of HSK44459 for idiopathic pulmonary fibrosis has completed.
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis [Phase 3]
A Phase III multicenter randomized double-blind trial to evaluate the efficacy and safety of HSK44459 tablets in idiopathic pulmonary fibros…
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis [Phase 2]
A Phase 2 clinical trial evaluating ABBV-142 in adults with idiopathic pulmonary fibrosis to assess adverse events and changes in disease ac…
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial [NA]
The OPTIMIZE-ILD-1 trial aiming to optimize the diagnostic journey for interstitial lung disease is currently recruiting.